2025 Wrapped: Recce Pharmaceuticals wraps up a healthy past 12 months Posted on December 19, 2025 by recce_com 2025 Wrapped: Recce Pharmaceuticals wraps up a healthy past 12 months
Break it Down: Recce in pole position for mega tax rebate Posted on December 17, 2025 by recce_com Break it Down: Recce in pole position for mega tax rebate
R327 shows strong efficacy in lung infection trial Posted on December 3, 2025 by recce_com R327 shows strong efficacy in lung infection trial
WHO 2025 Antibacterial Pipeline Report Posted on October 20, 2025October 20, 2025 by recce_com WHO 2025 Antibacterial Pipeline Report
Recce Pharmaceuticals Targets Diabetic Foot Infections With First-in-Class Synthetic Anti-Infective Posted on October 9, 2025 by recce_com Recce Pharmaceuticals Targets Diabetic Foot Infections With First-in-Class Synthetic Anti-Infective
Recce’s RECCE® 327 Topical Gel targets superbugs, speeds wound healing Posted on August 19, 2025 by recce_com Recce’s RECCE® 327 Topical Gel targets superbugs, speeds wound healing
RECCE® 327 Topical Gel shows strong preclinical results Posted on August 19, 2025August 19, 2025 by recce_com RECCE® 327 Topical Gel shows strong preclinical results
Recce secures $30m debt facility to support Phase III trials Posted on June 18, 2025 by recce_com Recce secures $30m debt facility to support Phase III trials
Break it Down: Recce partners with the US Army Posted on April 28, 2025 by recce_com Break it Down: Recce partners with the US Army
Recce to expand Phase II trial for diabetic foot infections Posted on April 22, 2025 by recce_com Recce to expand Phase II trial for diabetic foot infections
